-
Trial watch: local anesthetics in cancer therapy Oncoimmunology (IF 7.2) Pub Date : 2024-03-17 Killian Carnet Le Provost, Oliver Kepp, Guido Kroemer, Lucillia Bezu
Preclinical evidence indicates potent antitumor properties of local anesthetics. Numerous underlying mechanisms explaining such anticancer effects have been identified, suggesting direct cytotoxic ...
-
Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma Oncoimmunology (IF 7.2) Pub Date : 2024-03-15 Vikram S. Pothuri, Graham D. Hogg, Leah Conant, Nicholas Borcherding, C. Alston James, Jacqueline Mudd, Greg Williams, Yongwoo David Seo, William G. Hawkins, Venu G. Pillarisetty, David G. DeNardo, Ryan C. Fields
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is refractory to immune checkpoint inhibitor therapy. However, intratumoral T-cell infiltration correlates with improved overall ...
-
Humoral complementomics – exploration of noninvasive complement biomarkers as predictors of renal cancer progression Oncoimmunology (IF 7.2) Pub Date : 2024-03-13 Margot Revel, Mikel Rezola Artero, Houcine Hamidi, Anne Grunenwald, Loris Blasco, Yann A. Vano, Stephane Marie Oudard, Rafael Sanchez-Salas, Petr Macek, Lara Rodriguez Sanchez, Xavier Cathelineau, Benoit Vedié, Catherine Sautes-Fridman, Wolf Herman Fridman, Lubka T. Roumenina, Marie-Agnes Dragon-Durey
Despite the progress of anti-cancer treatment, the prognosis of many patients with solid tumors is still dismal. Reliable noninvasive biomarkers are needed to predict patient survival and therapy r...
-
Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer Oncoimmunology (IF 7.2) Pub Date : 2024-03-12 Erin M. Dickey, Anna Bianchi, Haleh Amirian, Peter J. Hosein, Denise Faustman, Roberta Brambilla, Jashodeep Datta
Pancreatic cancer is characterized by extreme therapeutic resistance. In pancreatic cancers harboring high-risk genomes, we describe that cancer cell-neutrophil signaling circuitry provokes neutrop...
-
Trial watch: dexmedetomidine in cancer therapy Oncoimmunology (IF 7.2) Pub Date : 2024-03-11 Killian Carnet Le Provost, Oliver Kepp, Guido Kroemer, Lucillia Bezu
Dexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that is widely used in intensive and anesthetic care for its sedative and anxiolytic properties. DEX has the capacity to alleviat...
-
Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML Oncoimmunology (IF 7.2) Pub Date : 2024-03-06 Marcus Bauer, Nadja Jäkel, Andreas Wilfer, Anja Haak, Markus Eszlinger, Katalin Kelemen, Monika Haemmerle, Haifa Kathrin Al-Ali, Barbara Seliger, Claudia Wickenhauser
Genetic aberrations and immune escape are fundamental in MDS and CMML initiation and progression to sAML. Therefore, quantitative and spatial immune cell organization, expression of immune checkpoi...
-
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer? Oncoimmunology (IF 7.2) Pub Date : 2024-03-04 Zoltan Szallasi, Aurel Prosz, Zsofia Sztupinszki, Judit Moldvay
Immune checkpoint inhibitor therapy has dramatically improved survival in a significant subset of patients with several solid tumor types. Increasing the number of patients benefitting from this fo...
-
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma Oncoimmunology (IF 7.2) Pub Date : 2024-03-03 Giulio Cassanello, Alejandro Luna de Abia, Lorenzo Falchi
Immunotherapy has shaped the treatment approach to diffuse large B-cell lymphoma (DLBCL), with rituximab leading to remarkable improvements in outcomes for both relapsed and treatment-naïve patient...
-
Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma Oncoimmunology (IF 7.2) Pub Date : 2024-02-27 Wei Wei, Linqing Tian, Xiaoyan Zheng, Lei Zhong, Yuan Chen, Hui Dong, Guibing Zhang, Shibing Wang, Xiangmin Tong
Pancreatic ductal adenocarcinoma (PDAC) is currently difficult to treat, even when therapies are combined with immune checkpoint blockade (ICB). A novel strategy for immunotherapy would be to maxim...
-
Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer Oncoimmunology (IF 7.2) Pub Date : 2024-02-26 Jin Su, Xinyuan Mao, Lingzhi Wang, Zhian Chen, Weisheng Wang, Cuiyin Zhao, Guoxin Li, Weihong Guo, Yanfeng Hu
Lactate plays an important role in shaping immune tolerance in tumor microenvironment (TME) and correlates with poor prognosis in various solid tumors. Overcoming the immune resistance in an acidic...
-
Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells Oncoimmunology (IF 7.2) Pub Date : 2024-02-22 Hannah Jorinde Glöckner, Evelina Martinenaite, Thomas Landkildehus Lisle, Jacob Grauslund, Shamaila Ahmad, Özcan Met, Per Thor Straten, Mads Hald Andersen
Arginase-1 (Arg1) is expressed by regulatory myeloid cells in the tumor microenvironment (TME), where they play a pro-tumorigenic and T-cell suppressive role. Arg1-specific CD4+ and CD8+ memory T c...
-
A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity Oncoimmunology (IF 7.2) Pub Date : 2024-02-16 Diana I. Albu, Benjamin J. Wolf, Yan Qin, Xianzhe Wang, Amy Daniel Ulumben, Mei Su, Vivian Li, Eirene Ding, Jose Angel Gonzalo, Jason Kong, Ruturaj Jadhav, Nelly Kuklin, Alberto Visintin, Bing Gong, Thomas J. Schuetz
Combinatorial strategies, such as targeting different immune checkpoint receptors, hold promise to increase the breadth and duration of the response to cancer therapy. Here we describe the preclini...
-
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition Oncoimmunology (IF 7.2) Pub Date : 2024-02-07 Yikun Li, Peiliang Wang, Junhao Xu, Xiaonan Shi, Tianwen Yin, Feifei Teng
This study aimed to develop a computed tomography (CT)-based radiomics model capable of precisely predicting hyperprogression and pseudoprogression (PP) in patients with non-small cell lung cancer ...
-
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer Oncoimmunology (IF 7.2) Pub Date : 2024-02-06 Patrik Sundström, Nikita Dutta, William Rodin, Andreas Hallqvist, Sukanya Raghavan, Marianne Quiding Järbrink
Mucosal-associated invariant T (MAIT) cells constitute one of the most numerous unconventional T cell subsets, and are characterized by rapid release of Th1- and Th17-associated cytokines and incre...
-
Platelet-derived microparticles adoptively transfer integrin β3 to promote antitumor effect of tumor-infiltrating T cells Oncoimmunology (IF 7.2) Pub Date : 2024-01-16 Mimi Zhou, Yali Feng, Xiaoli Zhang, Jianguo Chen, Naijuan Yao, Shan Fu, Tianzhi Ni, Yi Chen, Fei Xie, Sahasrabda Roy, Jinfeng Liu, Yuan Yang, Yingli He, Yingren Zhao, Nan Yang
Approximately two-thirds of hepatocellular carcinoma (HCC) is considered a “cold tumor” characterized by few tumor-infiltrating T cells and an abundance of immunosuppressive cells. Cilengitide, an ...
-
An oncogene regulating chromatin favors response to immunotherapy Oncoimmunology (IF 7.2) Pub Date : 2024-01-09 Leqian Ying, Zhangmin Hu, Yi Lu, Qing Tao, Fen Xiong, Yongqian Shu, Yufei Yang, Xuehan Qiao, Chen Peng, Yuchun Jiang, Miao Han, Min Xu, Xiaoqin Li, Deqiang Wang
Many biological processes related to cell function and fate begin with chromatin alterations, and many factors associated with the efficacy of immune checkpoint inhibitors (ICIs) are actually downs...
-
Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function Oncoimmunology (IF 7.2) Pub Date : 2024-01-05 Carlo P. Ramil, Handan Xiang, Peng Zhang, Aileen Cronin, Lisia Cabral, Zhizhang Yin, Josephine Hai, Huijun Wang, Benjamin Ruprecht, Yanlin Jia, Dongyu Sun, Hongmin Chen, An Chi
Myeloid cells are known to play a crucial role in creating a tumor-promoting and immune suppressive microenvironment. Our previous study demonstrated that primary human monocytes can be polarized i...
-
Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy Oncoimmunology (IF 7.2) Pub Date : 2024-01-08 Ying Zheng, Andriana Lebid, Liam Chung, Juan Fu, Xiaoxu Wang, Andrea Otrocol, Jelani C. Zarif, Hong Yu, Nicolas J. Llosa, Drew M. Pardoll
Activins, members of the TGF-beta superfamily, have been isolated and identified in the endocrine system, but have not been substantially investigated in the context of the immune system and endocr...
-
Single-cell analysis of T lymphocytes infiltrating colorectal carcinoma: the dilemma of specificity Oncoimmunology (IF 7.2) Pub Date : 2024-01-04 Manuela Lizarralde-Guerrero, Laura Zucaro, Guido Kroemer, Jonathan G. Pol
Advances in single-cell RNA and T cell receptor (TCR) sequencing allow to study the specificity and functionality of tumor-infiltrating T lymphocytes. A recent study unravels fundamental difference...
-
Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I interferon combination therapy Oncoimmunology (IF 7.2) Pub Date : 2023-12-27 Suyang Wang, Michelle Cheng, Chao-Cheng Chen, Chia-Yu Chang, Ya-Chea Tsai, Jr-Ming Yang, TC Wu, Chuan-Hsiang Huang, Chien-Fu Hung
Bacteria-based cancer therapy employs various strategies to combat tumors, one of which is delivering tumor-associated antigen (TAA) to generate specific immunity. Here, we utilized a poly-arginine...
-
Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis Oncoimmunology (IF 7.2) Pub Date : 2023-12-27 Jochen T. Frueh, Julia Campe, Daniele Yumi Sunaga-Franze, Nikita A. Verheyden, Sakhila Ghimire, Elisabeth Meedt, Denise Haslinger, Sabine Harenkamp, Daniel Staudenraus, Sascha Sauer, Andreas Kreft, Ralf Schubert, Michael Lohoff, Andreas Krueger, Halvard Bonig, Andreas G. Chiocchetti, Robert Zeiser, Ernst Holler, Evelyn Ullrich
Interferon regulatory factor 4 (IRF4) is a master transcription factor that regulates T helper cell (Th) differentiation. It interacts with the Basic leucine zipper transcription factor, ATF-like (...
-
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response Oncoimmunology (IF 7.2) Pub Date : 2023-12-26 Nadine Landolina, Francesca Romana Mariotti, Andrea Pelosi, Valentina D’Oria, Tiziano Ingegnere, Claudia Alicata, Paola Vacca, Lorenzo Moretta, Enrico Maggi
IL-37 is a member of the IL-1 superfamily exerting anti-inflammatory functions in a number of diseases. Extracellular IL-37 triggers the inhibitory receptor IL-1R8 that is known to regulate differe...
-
Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer Oncoimmunology (IF 7.2) Pub Date : 2023-12-22 Lukas Heger, Gordon F. Heidkamp, Lukas Amon, Falk Nimmerjahn, Tobias Bäuerle, Andreas Maier, Ramona Erber, Arndt Hartmann, Carolin C. Hack, Matthias Ruebner, Hanna Huebner, Peter Fasching, Matthias W. Beckmann, Diana Dudziak
Breast cancer is the most common malignancy in women worldwide and a highly heterogeneous disease. Four different subtypes are described that differ in the expression of hormone receptors as well a...
-
CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy Oncoimmunology (IF 7.2) Pub Date : 2023-12-21 Coralie Schoumacher, Valentin Derangère, Gwladys Gaudillière-Le Dain, Titouan Huppe, David Rageot, Alis Ilie, Angélique Vienot, Christophe Borg, Franck Monnien, Frederic Bibeau, Caroline Truntzer, François Ghiringhelli, For the CGE-Pancreas investigators
Stratification of the prognosis of pancreatic cancer (PDAC) patients treated by surgery is based solely on clinical variables, such as tumor stage and node status. The development of biomarkers of ...
-
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies Oncoimmunology (IF 7.2) Pub Date : 2023-12-20 Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant
Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investig...
-
Clusterin protects mature dendritic cells from reactive oxygen species mediated cell death Oncoimmunology (IF 7.2) Pub Date : 2023-12-18 Alvaro López Malizia, Antonela Merlotti, Pierre-Emmanuel Bonte, Melina Sager, Yago Arribas De Sandoval, Christel Goudot, Fernando Erra Díaz, Pehuén Pereyra-Gerber, Ana Ceballos, Sebastian Amigorena, Jorge Geffner, Juan Sabatte
Dendritic cells (DCs) play a key role in the induction of the adaptive immune response. They capture antigens in peripheral tissues and prime naïve T lymphocytes, triggering the adaptive immune res...
-
LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8+ T cells for improving anti-PD-1 antibody therapy Oncoimmunology (IF 7.2) Pub Date : 2023-12-14 Jiqi Shan, Wei Jing, Yu Ping, Chunyi Shen, Dong Han, Fengsen Liu, Yaqing Liu, Congcong Li, Yi Zhang
Anti-PD-1 antibody therapy has achieved success in tumor treatment; however, the duration of its clinical benefits are typically short. The functional state of intratumoral CD8+ T cells substantial...
-
MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4+ T cells in vivo Oncoimmunology (IF 7.2) Pub Date : 2023-12-10 Thomas V. Guy, Alexandra M. Terry, Helen M. McGuire, Elena Shklovskaya, Barbara Fazekas de St Groth
There has been growing interest in the role of B cells in antitumour immunity and potential use in adoptive cellular therapies. To date, the success of such therapies is limited. The intrinsic capa...
-
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma Oncoimmunology (IF 7.2) Pub Date : 2023-12-07 Morten Nielsen, Tine Monberg, Vibeke Sundvold, Benedetta Albieri, Dorrit Hovgaard, Michael Mørk Petersen, Anders Krarup-Hansen, Özcan Met, Ketil Camilio, Trevor Clancy, Richard Stratford, Baldur Sveinbjornsson, Øystein Rekdal, Niels Junker, Inge Marie Svane
LTX-315 is an oncolytic peptide that elicits both local and systemic immune responses upon intratumoral injection. In the present pilot trial, we treated patients with metastatic soft tissue sarcom...
-
Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases Oncoimmunology (IF 7.2) Pub Date : 2023-12-07 Meichen Li, Jing Chen, Hui Yu, Baishen Zhang, Xue Hou, Honghua Jiang, Dan Xie, Likun Chen
Immunotherapy has shown intracranial efficacy in non-small cell lung cancer (NSCLC) patients with brain metastases. However, predictive biomarkers for intracranial response to immunotherapy are lac...
-
Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer Oncoimmunology (IF 7.2) Pub Date : 2023-11-30 Hélène Poinot, Eloïse Dupuychaffray, Grégoire Arnoux, Montserrat Alvarez, Jérémie Tachet, Ounss Ezzar, Jonathan Moore, Olivia Bejuy, Eulalia Olesti, Gioele Visconti, Víctor González-Ruiz, Serge Rudaz, Jean-Christophe Tille, Clarissa D. Voegel, Patrycja Nowak-Sliwinska, Carole Bourquin, Aurélien Pommier
Although immune-based therapies have revolutionized the management of cancer, novel approaches are urgently needed to improve their outcome. We investigated the role of endogenous steroids in the r...
-
PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma Oncoimmunology (IF 7.2) Pub Date : 2023-12-01 Mengjia Song, Yue Huang, Ye Hong, Juan Liu, Jia Zhu, Suying Lu, Juan Wang, Feifei Sun, Junting Huang, Jiaqian Xu, Yan Tang, Jian-Chuan Xia, Yizhuo Zhang
T/NK cell-based immunotherapy has achieved remarkable success in adult cancers but has limited efficacy in pediatric malignancies including high-risk neuroblastoma (NB). Immune defects of NB tumor ...
-
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC Oncoimmunology (IF 7.2) Pub Date : 2023-11-27 Huiting Wu, Chang Liu, Qiang Yuan, Yan Qiao, Yongwei Ding, Lina Duan, Wenjing Li, Mengjia Zhang, Xuhua Zhang, Yanan Jiang, Jing Lu, Ziming Dong, Tao Wang, Kangdong Liu, Jimin Zhao
Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor of the digestive tract with a low 5-year survival rate due to the lack of effective treatment methods. Although therapeutic ...
-
Identification and characterization of the anti-viral interferon lambda 3 as direct target of the Epstein-Barr virus microRNA-BART7-3p Oncoimmunology (IF 7.2) Pub Date : 2023-11-27 Juliane Blümke, Marcus Bauer, Christoforos Vaxevanis, Andreas Wilfer, Ofer Mandelboim, Claudia Wickenhauser, Barbara Seliger, Simon Jasinski-Bergner
The human Epstein–Barr virus (EBV), as a member of the human γ herpes viruses (HHV), is known to be linked with distinct tumor types. It is a double-stranded DNA virus and its genome encodes among ...
-
Trial watch: beta-blockers in cancer therapy Oncoimmunology (IF 7.2) Pub Date : 2023-11-27 Killian Carnet Le Provost, Oliver Kepp, Guido Kroemer, Lucillia Bezu
Compelling evidence supports the hypothesis that stress negatively impacts cancer development and prognosis. Irrespective of its physical, biological or psychological source, stress triggers a phys...
-
Cell type-specific induction of ferroptosis to boost antitumor immunity Oncoimmunology (IF 7.2) Pub Date : 2023-11-20 Jiao Liu, Jingbo Li, Rui Kang, Daolin Tang
Traditional ferroptosis activators typically suppress antitumor immunity. Our discovery shows that N6F11, a small molecule compound, can selectively induce ferroptosis by targeting TRIM25-mediated ...
-
g-NK cells from umbilical cord blood are phenotypically and functionally different than g-NK cells from peripheral blood Oncoimmunology (IF 7.2) Pub Date : 2023-11-22 Fei Gao, Mauricio Campos Mora, Michael Constantinides, Loïs Coenon, Caroline Multrier, Loïc Vaillant, Tianxiang Zhang, Martin Villalba
FcRγ-deficient natural killer (NK) cells, designated as g-NK cells, exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) capacity and increased IFN-γ and TNF-α production, rendering the...
-
The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis Oncoimmunology (IF 7.2) Pub Date : 2023-11-20 Ángela Bella, Ignacio Melero, Pedro Berraondo, Fernando Aranda
Our recent research has unveiled the potential of locoregional immunotherapy. Cytokine-armored viral vectors, such as modified vaccinia virus Ankara vector encoding single-chain interleukin-12 (MVA...
-
Piezo1 facilitates optimal T cell activation during tumor challenge Oncoimmunology (IF 7.2) Pub Date : 2023-11-22 muta abiff, Mohammad Alshebremi, Melissa Bonner, Jay T. Myers, Byung-Gyu Kim, Suzanne L. Tomchuck, Alicia Santin, Daniel Kingsley, Sung Hee Choi, Alex Y. Huang
Functional effector T cells in the tumor microenvironment (TME) are critical for successful anti-tumor responses. T cell anti-tumor function is dependent on their ability to differentiate from a na...
-
Tumor-intrinsic RGS1 potentiates checkpoint blockade response via ATF3-IFNGR1 axis Oncoimmunology (IF 7.2) Pub Date : 2023-11-20 Baojun Wang, Bo Jiang, Lin Du, Wenyuan Chen, Qing Zhang, Wei Chen, Meng Ding, Wenmin Cao, Jie Gao, Yongming Deng, Yao Fu, Yan Li, Yonglong Xiao, Wenli Diao, Hongqian Guo
Non-responsiveness is a major barrier in current cancer immune checkpoint blockade therapies, and the mechanism has not been elucidated yet. Therefore, it is necessary to discover the mechanism and...
-
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer Oncoimmunology (IF 7.2) Pub Date : 2023-11-13 Maximilian Marhold, Simon Udovica, Anna Halstead, Mona Hirdler, Muna Ferner, Kerstin Wimmer, Zsuzsanna Bago-Horvath, Ruth Exner, Florian Fitzal, Kathrin Strasser-Weippl, Tim Robinson, Rupert Bartsch
Based upon results of the KEYNOTE-522 trial and following approval by regulatory authorities, the addition of pembrolizumab to chemotherapy is now the standard-of-care for the treatment of early tr...
-
Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors Oncoimmunology (IF 7.2) Pub Date : 2023-11-09 Lucillia Bezu, Oliver Kepp, Guido Kroemer
Recent clinical trials have compared the use of different chemotherapeutic regimens as “immune induction therapies” to sensitize cancers to immune checkpoint inhibitors (ICI). Cytotoxic drugs reput...
-
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy Oncoimmunology (IF 7.2) Pub Date : 2023-11-05 Nils-Petter Rudqvist, Manushak Avagyan, Dhan Chand
Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as b...
-
Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia Oncoimmunology (IF 7.2) Pub Date : 2023-11-03 Iria Fernandez Botana, Giulia Pagano, Etienne Moussay, Jerome Paggetti
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. It is characterized by a high dependency on interactions with the surrounding immune landscape, highlighti...
-
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases Oncoimmunology (IF 7.2) Pub Date : 2023-10-30 Pankti Reid, Sabina Sandigursky, Juhee Song, Maria A. Lopez-Olivo, Houssein Safa, Samuel Cytryn, Elizaveta Efuni, Maryam Buni, Anna Pavlick, Michelle Krogsgaard, Osama Abu-Shawer, Mehmet Altan, Jeffrey S. Weber, Osama E. Rahma, Maria E. Suarez-Almazor, Adi Diab, Noha Abdel-Wahab
Patients with preexisting autoimmune disease (pAID) are generally excluded from clinical trials for immune checkpoint inhibitors (ICIs) for cancer due to concern of flaring pAID. In this multi-cent...
-
Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients Oncoimmunology (IF 7.2) Pub Date : 2023-10-24 Sandra García-Mulero, Roberto Fornelino, Marco Punta, Stefano Lise, Mar Varela, Luis P. del Carpio, Rafael Moreno, Marcel Costa-García, Dietmar Rieder, Zlatko Trajanoski, Alena Gros, Ramón Alemany, Josep María Piulats, Rebeca Sanz-Pamplona
Uveal melanoma (UM) is the most common ocular malignancy in adults. Nearly 95% of UM patients carry the mutually exclusive mutations in the homologous genes GNAQ (amino acid change Q209L/Q209P) and...
-
CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis Oncoimmunology (IF 7.2) Pub Date : 2023-10-20 Tao Zhang, Ramez Wahib, Dimitra E. Zazara, Jöran Lücke, Ahmad Mustafa Shiri, Jan Kempski, Lilan Zhao, Theodora Agalioti, Andres Pablo Machicote, Olympia Giannou, Ioannis Belios, Rongrong Jia, Siwen Zhang, Joseph Tintelnot, Hannes Seese, Julia Kristin Grass, Baris Mercanoglu, Louisa Stern, Pasquale Scognamiglio, Mohammad Fard-Aghaie, Philipp Seeger, Jonas Wakker, Marius Kemper, Benjamin Brunswig, Anna
Metastasis is a cancer-related systemic disease and is responsible for the greatest mortality rate among cancer patients. Interestingly, the interaction between the immune system and cancer cells s...
-
PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma Oncoimmunology (IF 7.2) Pub Date : 2023-10-19 Niklas Klümper, Lennert Wüst, Jonas Saal, Damian J. Ralser, Romina Zarbl, Jonas Jarczyk, Johannes Breyer, Danijel Sikic, Bernd Wullich, Christian Bolenz, Florian Roghmann, Michael Hölzel, Manuel Ritter, Sebastian Strieth, Arndt Hartmann, Philipp Erben, Ralph M. Wirtz, Jennifer Landsberg, Dimo Dietrich, Markus Eckstein
PD-L1 status assessed by immunohistochemistry (IHC) has failed to reliably predict outcomes for patients with metastatic urothelial carcinoma (mUC) on immune checkpoint blockade (ICB). PD-L1 promot...
-
Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues Oncoimmunology (IF 7.2) Pub Date : 2023-10-20 Qikang Hu, Meredith L. Frank, Yang Gao, Liyan Ji, Muyun Peng, Chen Chen, Bin Wang, Yan Hu, Zeyu Wu, Jina Li, Lu Shu, Qiongzhi He, Yingqian Zhang, Xuefeng Xia, Jianjun Zhang, Xin Yi, Alexandre Reuben, Fenglei Yu
A better understanding of T cells in lung cancer and their distribution across tumor-adjacent lungs and peripheral blood is needed to improve efficacy and minimize toxicity from immunotherapy to lu...
-
A mitochondrial checkpoint to adaptive anticancer immunity Oncoimmunology (IF 7.2) Pub Date : 2023-10-16 Oliver Kepp, Peng Liu, Guido Kroemer, Lorenzo Galluzzi
BCL2 robustly preserves mitochondrial integrity, hence inhibiting innate immune signaling and apoptotic cell death in several cell types. Here, we comment on our recent data demonstrating that BCL2...
-
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody Oncoimmunology (IF 7.2) Pub Date : 2023-10-16 Hayat Bähr-Mahmud, Ursula Ellinghaus, Christiane R. Stadler, Leyla Fischer, Claudia Lindemann, Anuhar Chaturvedi, Jan Diekmann, Stefan Wöll, Imke Biermann, Bernhard Hebich, Caroline Scharf, Manuela Siefke, Alexandra S. Roth, Martin Rao, Kerstin Brettschneider, Eva-Maria Ewen, Uğur Şahin, Özlem Türeci
IMAB362/Zolbetuximab, a first-in-class IgG1 antibody directed against the cancer-associated gastric-lineage marker CLDN18.2, has recently been reported to have met its primary endpoint in two phase...
-
Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration Oncoimmunology (IF 7.2) Pub Date : 2023-10-12 Yu Tian, Lingyi Kong, Yan Li, Zhiyun Liao, Xing Cai, Suke Deng, Xiao Yang, Bin Zhang, Yijun Wang, Zhanjie Zhang, Bian Wu, Lu Wen, Fang Huang, Yan Hu, Chao Wan, Yifei Liao, Yajie Sun, Kunyu Yang
Radiotherapy could regulate systemic antitumor immunity, while the immune state in the tumor microenvironment (TME) also affects the efficacy of radiotherapy. We have found that higher CD8+ T cell ...
-
Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor Oncoimmunology (IF 7.2) Pub Date : 2023-10-05 Jingjing Zhao, Jiebin Dong, Changwen Deng, Qianjing Zhang, Shicheng Sun, Honggang Li, Yun Bai, Hongkui Deng
Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated success in the treatment of hematological malignancies; however, its efficacy and applications in solid tumors remain limited. ...
-
Interleukin-17 signaling influences CD8+ T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells Oncoimmunology (IF 7.2) Pub Date : 2023-10-05 Constanza Rodriguez, Cintia L. Araujo Furlan, Jimena Tosello Boari, Sabrina N. Bossio, Santiago Boccardo, Laura Fozzatti, Fernando P. Canale, Cristian G. Beccaria, Nicolás G. Nuñez, Danilo G. Ceschin, Eliane Piaggio, Adriana Gruppi, Carolina L. Montes, Eva V. Acosta Rodríguez
IL-17 immune responses in cancer are controversial, with both tumor-promoting and tumor-repressing effects observed. To clarify the role of IL-17 signaling in cancer progression, we used syngeneic ...
-
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies Oncoimmunology (IF 7.2) Pub Date : 2023-10-04 Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer
Lymphocyte-activation gene-3 (LAG-3), an immune checkpoint receptor, negatively regulates T-cell function and facilitates immune escape of tumors. Dual inhibition of LAG-3 and programmed cell death...
-
C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer Oncoimmunology (IF 7.2) Pub Date : 2023-09-30 Chen Zhang, Kankan Cao, Moran Yang, Yiying Wang, Mengdi He, Jiaqi Lu, Yan Huang, Guodong Zhang, Haiou Liu
High-grade serous ovarian cancer (HGSC), with a modest response to immune checkpoint blockade (ICB) targeting PD-1/PD-L1 monotherapy, is densely infiltrated by M2-polarized tumor-associated macroph...
-
Non-pharmaceutical interventions to optimize cancer immunotherapy Oncoimmunology (IF 7.2) Pub Date : 2023-09-28 Maximilian Boesch, Florent Baty, Frank Rassouli, Tobias Kowatsch, Markus Joerger, Martin Früh, Martin H. Brutsche
The traditional picture of cancer patients as weak individuals requiring maximum rest and protection is beginning to dissolve. Too much focus on the medical side and one’s own vulnerability and mor...
-
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection Oncoimmunology (IF 7.2) Pub Date : 2023-09-28 Trevor S. Anderson, Amanda L. McCormick, Elizabeth A. Daugherity, Mariam Oladejo, Izuchukwu F. Okpalanwaka, Savanna L. Smith, Duke Appiah, Laurence M. Wood, Devin B. Lowe
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality despite efforts to improve standard interventions. As CRC patients can benefit from immunotherapeutic strategies that inc...
-
Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy Oncoimmunology (IF 7.2) Pub Date : 2023-09-27 Sandra Martinez-Morilla, Myrto Moutafi, Aileen I. Fernandez, Shlomit Jessel, Prajan Divakar, Pok Fai Wong, Rolando Garcia-Milian, Kurt A. Schalper, Harriet M. Kluger, David L. Rimm
Although immune checkpoint inhibitor (ICI) therapy has dramatically improved outcome for metastatic melanoma patients, many patients do not benefit. Since adverse events may be severe, biomarkers f...
-
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis Oncoimmunology (IF 7.2) Pub Date : 2023-09-20 Eun-Jin Go, Hannah Yang, Seung Joon Lee, Hyun Gul Yang, Jin A. Shin, Won Suk Lee, Hye Seong Lim, Hong Jae Chon, Chan Kim
Antiangiogenic therapy is a recognized method for countering the immunosuppressive tumor microenvironment (TME) and improving anti-tumor immunity. PB101 is a glycosylated decoy receptor that binds ...